marked.bio

Company

Nuvation Bio

7 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 4 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

taletrectinib 4safusidenib 3crizotinib 1

Trials

7 of 10 trials shown

  1. Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

    Not yet recruiting Phase 3 Nuvation Bio Starts 2027Primary completion 2029-05 NCT07712757

    safusidenib

    Histologically confirmed Grade 2, IDH1-mutant oligodendroglioma or astrocytoma according to World Health Organization Central Nervous S…

    IDH1/2 mutationGrade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2, Oligodendroglioma, Oligodendroglioma IDH-mutant and 1p/19q-codeleted

  2. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

    Recruiting Phase 3 Nuvation Bio Started 2025Primary completion 2030-08 NCT07154706

    taletrectinib FDA

    Documented ROS1 rearrangement in primary tumor by a validated local assay performed in CLIA-certified or locally equiva…

    ROS1 fusionNon-small Cell Lung Cancer (NSCLC)

  3. A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

    Recruiting Phase 3 Nuvation Bio Started 2024Primary completion 2029-01 NCT06564324

    taletrectinib FDAcrizotinib FDA EU

    Have documentation of ROS1 rearrangement by a positive result

    ROS1 fusionNon Small Cell Lung Cancer

  4. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    Recruiting Phase 3 Nuvation Bio Started 2023Primary completion 2028-12 NCT05303519

    safusidenib

    …stologically confirmed recurrent or progressive WHO Grade 2 glioma or Grade 3 glioma with IDH1 R132H or R132C mutation confirmed by immunohistochemistry or molecular genetic testing.

    IDH1/2 mutationGlioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3

  5. Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

    Recruiting Phase 2 Nuvation Bio Starts 2027Primary completion 2030-09 NCT07703436

    safusidenib

    Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 20…

    IDH1/2 mutationGrade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma

  6. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

    Active, not recruiting Phase 2 Nuvation Bio Started 2021Primary completion 2025-06 NCT04919811

    taletrectinib FDA

    Evidence of ROS1 fusion by a validated assay as performed in Clinical Laboratory Improvement Amendments (CLIA)-ce…

    ROS1 fusionNon Small Cell Lung Cancer

  7. A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

    Active, not recruiting Phase 2 Nuvation Bio Started 2020Primary completion 2024-06 NCT04395677

    taletrectinib FDA

    Positivity of ROS1 fusion is determined by the local qualified laboratories by using the FISH, RT-PCR or NGS assay,…

    ROS1 fusionNon Small Cell Lung Cancer